Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function

Yoshito Tomimaru, Hidetoshi Eguchi, Taroh Satoh, Akira Tomokuni, Tadafumi Asaoka, Hiroshi Wada, Shigeru Marubashi, Kazuhiko Ogawa, Tetsuo Takehara, Masaki Mori, Yuichiro Doki, Hiroaki Nagano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Although pre-operative chemoradiotherapy appears to be a promising treatment for patients with pancreatic ductal adenocarcinoma, there have been no reports of the feasibility of preoperative chemoradiotherapy in pancreatic ductal adenocarcinoma patients with renal impairment. The aim of this study was to evaluate retrospectively the feasibility of pre-operative chemoradiotherapy in pancreatic ductal adenocarcinoma patients with renal impairment. Methods: Twelve patients with resectable pancreatic ductal adenocarcinoma and a creatinine clearance of <60 ml/min were enrolled in this study. Gemcitabine-based pre-operative chemoradiotherapy was performed, followed by surgery. The feasibility of the treatment was evaluated in terms of clinical outcome and adverse events in the patients. Results: All 12 patients completed gemcitabine-based pre-operative chemoradiotherapy without worsening of renal function. Restaging after the therapy revealed radiologically unresectable disease in two patients. Among the remaining 10 patients who underwent laparotomy, curative resection was performed in eight patients. After curative resection, five patients out of the eight completed post-operative adjuvant therapy. The 1-and 3-year survival rates after the start of chemoradiotherapy in the 12 patients were 80.8 and 36.9%, respectively. Conclusions: Our findings suggest that gemcitabine-based pre-operative chemoradiotherapy may be a safe and effective treatment for pancreatic ductal adenocarcinoma in patients with renal impairment.

Original languageEnglish
Pages (from-to)343-348
Number of pages6
JournalJapanese journal of clinical oncology
Volume45
Issue number4
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

gemcitabine
Chemoradiotherapy
Pancreatic Neoplasms
Kidney
Adenocarcinoma
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. / Tomimaru, Yoshito; Eguchi, Hidetoshi; Satoh, Taroh; Tomokuni, Akira; Asaoka, Tadafumi; Wada, Hiroshi; Marubashi, Shigeru; Ogawa, Kazuhiko; Takehara, Tetsuo; Mori, Masaki; Doki, Yuichiro; Nagano, Hiroaki.

In: Japanese journal of clinical oncology, Vol. 45, No. 4, 01.01.2015, p. 343-348.

Research output: Contribution to journalArticle

Tomimaru, Y, Eguchi, H, Satoh, T, Tomokuni, A, Asaoka, T, Wada, H, Marubashi, S, Ogawa, K, Takehara, T, Mori, M, Doki, Y & Nagano, H 2015, 'Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function', Japanese journal of clinical oncology, vol. 45, no. 4, pp. 343-348. https://doi.org/10.1093/jjco/hyu224
Tomimaru, Yoshito ; Eguchi, Hidetoshi ; Satoh, Taroh ; Tomokuni, Akira ; Asaoka, Tadafumi ; Wada, Hiroshi ; Marubashi, Shigeru ; Ogawa, Kazuhiko ; Takehara, Tetsuo ; Mori, Masaki ; Doki, Yuichiro ; Nagano, Hiroaki. / Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. In: Japanese journal of clinical oncology. 2015 ; Vol. 45, No. 4. pp. 343-348.
@article{43ddace0da1241658e939918a6aca18f,
title = "Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function",
abstract = "Objective: Although pre-operative chemoradiotherapy appears to be a promising treatment for patients with pancreatic ductal adenocarcinoma, there have been no reports of the feasibility of preoperative chemoradiotherapy in pancreatic ductal adenocarcinoma patients with renal impairment. The aim of this study was to evaluate retrospectively the feasibility of pre-operative chemoradiotherapy in pancreatic ductal adenocarcinoma patients with renal impairment. Methods: Twelve patients with resectable pancreatic ductal adenocarcinoma and a creatinine clearance of <60 ml/min were enrolled in this study. Gemcitabine-based pre-operative chemoradiotherapy was performed, followed by surgery. The feasibility of the treatment was evaluated in terms of clinical outcome and adverse events in the patients. Results: All 12 patients completed gemcitabine-based pre-operative chemoradiotherapy without worsening of renal function. Restaging after the therapy revealed radiologically unresectable disease in two patients. Among the remaining 10 patients who underwent laparotomy, curative resection was performed in eight patients. After curative resection, five patients out of the eight completed post-operative adjuvant therapy. The 1-and 3-year survival rates after the start of chemoradiotherapy in the 12 patients were 80.8 and 36.9{\%}, respectively. Conclusions: Our findings suggest that gemcitabine-based pre-operative chemoradiotherapy may be a safe and effective treatment for pancreatic ductal adenocarcinoma in patients with renal impairment.",
author = "Yoshito Tomimaru and Hidetoshi Eguchi and Taroh Satoh and Akira Tomokuni and Tadafumi Asaoka and Hiroshi Wada and Shigeru Marubashi and Kazuhiko Ogawa and Tetsuo Takehara and Masaki Mori and Yuichiro Doki and Hiroaki Nagano",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/jjco/hyu224",
language = "English",
volume = "45",
pages = "343--348",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function

AU - Tomimaru, Yoshito

AU - Eguchi, Hidetoshi

AU - Satoh, Taroh

AU - Tomokuni, Akira

AU - Asaoka, Tadafumi

AU - Wada, Hiroshi

AU - Marubashi, Shigeru

AU - Ogawa, Kazuhiko

AU - Takehara, Tetsuo

AU - Mori, Masaki

AU - Doki, Yuichiro

AU - Nagano, Hiroaki

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: Although pre-operative chemoradiotherapy appears to be a promising treatment for patients with pancreatic ductal adenocarcinoma, there have been no reports of the feasibility of preoperative chemoradiotherapy in pancreatic ductal adenocarcinoma patients with renal impairment. The aim of this study was to evaluate retrospectively the feasibility of pre-operative chemoradiotherapy in pancreatic ductal adenocarcinoma patients with renal impairment. Methods: Twelve patients with resectable pancreatic ductal adenocarcinoma and a creatinine clearance of <60 ml/min were enrolled in this study. Gemcitabine-based pre-operative chemoradiotherapy was performed, followed by surgery. The feasibility of the treatment was evaluated in terms of clinical outcome and adverse events in the patients. Results: All 12 patients completed gemcitabine-based pre-operative chemoradiotherapy without worsening of renal function. Restaging after the therapy revealed radiologically unresectable disease in two patients. Among the remaining 10 patients who underwent laparotomy, curative resection was performed in eight patients. After curative resection, five patients out of the eight completed post-operative adjuvant therapy. The 1-and 3-year survival rates after the start of chemoradiotherapy in the 12 patients were 80.8 and 36.9%, respectively. Conclusions: Our findings suggest that gemcitabine-based pre-operative chemoradiotherapy may be a safe and effective treatment for pancreatic ductal adenocarcinoma in patients with renal impairment.

AB - Objective: Although pre-operative chemoradiotherapy appears to be a promising treatment for patients with pancreatic ductal adenocarcinoma, there have been no reports of the feasibility of preoperative chemoradiotherapy in pancreatic ductal adenocarcinoma patients with renal impairment. The aim of this study was to evaluate retrospectively the feasibility of pre-operative chemoradiotherapy in pancreatic ductal adenocarcinoma patients with renal impairment. Methods: Twelve patients with resectable pancreatic ductal adenocarcinoma and a creatinine clearance of <60 ml/min were enrolled in this study. Gemcitabine-based pre-operative chemoradiotherapy was performed, followed by surgery. The feasibility of the treatment was evaluated in terms of clinical outcome and adverse events in the patients. Results: All 12 patients completed gemcitabine-based pre-operative chemoradiotherapy without worsening of renal function. Restaging after the therapy revealed radiologically unresectable disease in two patients. Among the remaining 10 patients who underwent laparotomy, curative resection was performed in eight patients. After curative resection, five patients out of the eight completed post-operative adjuvant therapy. The 1-and 3-year survival rates after the start of chemoradiotherapy in the 12 patients were 80.8 and 36.9%, respectively. Conclusions: Our findings suggest that gemcitabine-based pre-operative chemoradiotherapy may be a safe and effective treatment for pancreatic ductal adenocarcinoma in patients with renal impairment.

UR - http://www.scopus.com/inward/record.url?scp=84926488466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926488466&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyu224

DO - 10.1093/jjco/hyu224

M3 - Article

C2 - 25589454

AN - SCOPUS:84926488466

VL - 45

SP - 343

EP - 348

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 4

ER -